| 查看: 838 | 回复: 1 | ||
marineman至尊木虫 (知名作家)
爱八卦爱生活
|
[求助]
iPath2为何经常无法访问? 已有1人参与
|
|
http://pathways.embl.de 经常无法访问,可其他人都说可以。有时候上去了,输出结果图片也不成功。 Nucleic Acids Res. 2011 Jul;39(Web Server issue):W412-5. doi: 10.1093/nar/gkr313. Epub 2011 May 5. iPath2.0: interactive pathway explorer. Yamada T1, Letunic I, Okuda S, Kanehisa M, Bork P. Abstract iPath2.0 is a web-based tool (http://pathways.embl.de) for the visualization and analysis of cellular pathways. Its primary map summarizes the metabolism in biological systems as annotated to date. Nodes in the map correspond to various chemical compounds and edges represent series of enzymatic reactions. In two other maps, iPath2.0 provides an overview of secondary metabolite biosynthesis and a hand-picked selection of important regulatory pathways and other functional modules, allowing a more general overview of protein functions in a genome or metagenome. iPath2.0's main interface is an interactive Flash-based viewer, which allows users to easily navigate and explore the complex pathway maps. In addition to the default pre-computed overview maps, iPath offers several data mapping tools. Users can upload various types of data and completely customize all nodes and edges of iPath2.0's maps. These customized maps give users an intuitive overview of their own data, guiding the analysis of various genomics and metagenomics projects. |
» 猜你喜欢
恩诺沙星(Enrofloxacin)科研解析:分子特征、LC-MS/MS 检测与实验室使用要点
已经有0人回复
Calderasib理化性质与实验操作技术笔记
已经有0人回复
化学工程及工业化学论文润色/翻译怎么收费?
已经有280人回复
RMC-6291怎么用?RAS(ON) 三重复合物工具化合物的实验室实操要点
已经有0人回复
苯并呋咱全解析:NBD 荧光衍生化试剂母核的化学特性与实验室应用
已经有0人回复
生物质炭与活化剂氢氧化钾混合注意事项
已经有0人回复
科研人必读:新一代 KRAS G12C 抑制剂 Olomorasib 的研究进展
已经有0人回复
BT-11(Omilancor)研究化合物全解析:从分子结构到实验应用要点
已经有0人回复
富马酸贝达喹啉:二芳基喹啉类工具化合物的化学特征
已经有0人回复
BT投稿with editor状态快两周了,正常吗
已经有25人回复
Silevertinib(BDTX-1535)结构拆解:炔基双环片段为何成为合成瓶颈
已经有0人回复
晋鹏
版主 (知名作家)
- MolEPI: 6
- 应助: 626 (博士)
- 贵宾: 0.096
- 金币: 27592.6
- 散金: 1052
- 红花: 288
- 沙发: 2
- 帖子: 5663
- 在线: 726.4小时
- 虫号: 1183978
- 注册: 2011-01-05
- 性别: GG
- 专业: 生物信息学
- 管辖: 农林

2楼2017-10-07 20:42:16










回复此楼